NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (241)	12/8/1997 9:04:00 PM
From: Miljenko Zuanic	Read Replies (1) of 328

Peter and others: I guess the news on Abelcet, from ASH conference, contribute to recent weakness of the NXTR stock price: prnewswire.com This are not data from clinical trials, open or closed, and are selected patients from of-label usage. If someone think that this data will be base for ANDA Abelcet file for FUO indication, it is i very wrong. News indicate that part of the US Abelcet sale is from of-label usage which is well known. Also, one can speculate that AmBisome market window will be shorter and with difficulty to penetrate. To early to guess, but if EU sales comparison data are of any value, than outcome is easy to project. Anyway, did someone lately contacted NXTR IR and asked for France and expanded EU AmBisome approval (FUO and first line therapy)??? Thanks. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next